Blog

United Oil & Gas Plc (LSE:UOG) has launched a conditional fundraising round to raise approximately £2.33 million through the issuance of new ordinary shares, pending shareholder approval. The capital will be used to fund the company’s piston coring program at the Walton Morant Licence offshore Jamaica—a key initiative designed to enhance the Geological Chance of Success across priority exploration targets.

The program aims to strengthen United’s technical understanding of the area and improve its commercial positioning as it seeks future partnerships to advance development. The fundraising underscores the company’s commitment to progressing its high-impact exploration portfolio while maintaining financial discipline.

About United Oil & Gas Plc

United Oil & Gas Plc is an independent energy company engaged in oil and gas exploration and development, with a high-impact exploration license in Jamaica and a development asset in the UK. The company focuses on maturing its portfolio through technically driven exploration and strategic partnerships, with the goal of creating long-term shareholder value and expanding its presence in key hydrocarbon regions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

LondonMetric Property Plc (LSE:LMP) has reported robust results for the six months ending September 2025, achieving a 14% increase in net rental income alongside consistently high occupancy rates. The company has continued to refine its portfolio through targeted acquisitions and the disposal of non-core assets, driving strong rental growth while maintaining an efficient cost structure.

As part of its financial strategy, LondonMetric has undertaken a major refinancing initiative, replacing secured debt with more favorable unsecured facilities. This move strengthens the company’s balance sheet, enhances financial flexibility, and supports future investment opportunities. Recent acquisitions are integrating smoothly, further reinforcing the company’s momentum and commitment to delivering shareholder value.

LondonMetric’s solid financial results and attractive valuation underpin its strong investment appeal. Its combination of healthy revenue and profit growth, a sound capital structure, and an appealing P/E ratio and dividend yield contribute to a positive long-term outlook. However, technical indicators suggest limited short-term momentum, slightly moderating near-term expectations.

About LondonMetric Property

LondonMetric Property Plc is one of the UK’s leading triple net lease Real Estate Investment Trusts (REITs), managing a portfolio valued at approximately £7 billion. The company focuses on high-demand sectors including logistics, healthcare, convenience, entertainment, and leisure, providing well-located properties that deliver consistent, income-driven returns. LondonMetric’s strategy centers on owning and managing assets that align with occupier needs while generating long-term, sustainable value for shareholders.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

SpaceandPeople (LSE:SAL) has confirmed that trading remains consistent with its upgraded market guidance for the financial year ending December 2025, with expectations of sustained growth into 2026. The company projects revenue to reach £8.8 million in 2026, representing a 6% year-on-year increase, and anticipates profit before tax of £0.75 million, supported by lower borrowing costs following the full repayment of its term loan.

The company’s improved financial performance and favorable technical trends underpin its positive outlook. A balanced valuation further supports investor confidence, although the absence of a dividend yield and indications of potential overbought conditions are factors to monitor. Despite limited recent corporate announcements or earnings call updates, the overall outlook remains constructive.

About SpaceandPeople

SpaceandPeople is a specialist in brand experience, retail, and promotional space management, connecting brands with high-traffic venues to create impactful marketing activations and retail pop-ups. The company facilitates creative, flexible engagement solutions that help brands reach consumers directly in shopping centers, transport hubs, and other public spaces.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Innovative Eyewear, a subsidiary of Tekcapital Plc (LSE:TEK), has advanced its European growth strategy after a successful showcase at the SILMO Paris 2025 trade fair. The company secured its first orders from major European markets and established a new logistics hub in the Netherlands to enhance regional distribution efficiency.

By exhibiting in SILMO’s Tech Village alongside global technology leaders such as Meta and Google, Innovative Eyewear underscored its position at the forefront of AI-driven smart eyewear innovation. The company’s latest initiatives—including obtaining industrial safety certification for its Lucyd Armor line and expanding its network of regional sales representatives—are expected to accelerate market penetration and boost its share in Europe’s rapidly growing smart eyewear segment.

About Tekcapital

Tekcapital Plc is a UK-based intellectual property investment group focused on commercializing university-developed technologies that improve quality of life. Listed on the AIM market of the London Stock Exchange, Tekcapital holds a significant stake in Innovative Eyewear, Inc., which designs and sells Bluetooth-enabled smart glasses under brands such as Lucyd, Nautica, Eddie Bauer, and Reebok. Through its product range, Innovative Eyewear connects users seamlessly to their digital environments while offering diverse frame and lens options to suit different lifestyles and needs.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

AstraZeneca (LSE:AZN) has reported that its investigational treatment, baxdrostat, achieved the primary endpoint in the Phase III Bax24 trial, demonstrating a statistically significant reduction in 24-hour ambulatory systolic blood pressure among patients with resistant hypertension. The findings mark a major step forward in addressing a condition that remains difficult to manage with existing therapies.

Baxdrostat’s once-daily dosing regimen and sustained efficacy suggest it could redefine treatment standards for patients struggling with uncontrolled blood pressure, potentially lowering long-term cardiovascular risk. Following these results, AstraZeneca intends to move forward with regulatory submissions and explore the drug’s broader therapeutic potential in diseases driven by excess aldosterone activity, including primary aldosteronism and chronic kidney disease.

The company’s strong financial results and a confident tone during recent earnings calls have underpinned a favorable outlook. However, analysts note some caution around short-term technical indicators and valuation levels, with AstraZeneca’s shares trading at a premium. Despite these considerations, the firm’s diversified pipeline and strategic expansion initiatives continue to reinforce long-term growth prospects.

About AstraZeneca

Headquartered in Cambridge, UK, AstraZeneca is a global, science-driven biopharmaceutical company dedicated to discovering, developing, and commercializing prescription medicines. Its research focuses on Oncology, Rare Diseases, and BioPharmaceuticals—covering Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative treatments are available in more than 125 countries, helping improve health outcomes for millions of patients worldwide.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Eco Buildings Group plc (LSE:ECOB) has reached a key milestone in its partnership with G2 Invest Group in Senegal, advancing their joint venture into the execution stage. The initiative—operating under the name Eco Buildings Senegal Limited—forms part of the company’s broader goal to deliver a 10,000-home program, with an initial phase targeting 5,000 homes. These will be built using Eco’s proprietary modular construction systems, designed to deliver sustainable, affordable housing solutions at scale for emerging markets.

The project’s transition from planning to execution follows the mobilization of factory operations, with planning approvals expected before the end of the year. Once finalized, site construction will begin immediately. This development marks not only a substantial revenue opportunity but also a foundational step in establishing Eco Buildings’ operational footprint in West Africa, supporting its ambition to expand its modular housing model throughout the region.

Despite this strategic progress, the company continues to face financial headwinds, particularly in profitability and cash flow. While some technical indicators point to short-term positive momentum, the lack of consistent earnings and dividend returns continues to weigh on valuation. Additionally, limited investor communications, including the absence of earnings calls or corporate updates, constrain broader market assessment.

About Eco Buildings Group

Eco Buildings Group plc specializes in sustainable, prefabricated housing solutions built using Glass Fiber Reinforced Gypsum (GFRG) technology. Its modular systems enable rapid construction, reduced costs, and lower environmental impact—serving both affordable housing and high-end development markets. With a growing portfolio of international projects, Eco Buildings is positioning itself as a global leader in modern, eco-efficient construction innovation.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Oxford BioMedica (LSE:OXB) is deepening its presence in the United States through the acquisition of a large-scale viral vector manufacturing site in North Carolina from Resilience. The move supports the company’s strategy to expand its U.S. GMP manufacturing capacity, catering to increasing client demand while reinforcing its global network of contract development and manufacturing (CDMO) facilities.

The newly acquired site will play a key role in advancing late-stage development programs and commercial product launches, with a particular emphasis on adeno-associated virus (AAV) technologies. This addition is expected to enhance Oxford BioMedica’s competitive edge in the global viral vector sector and contribute to its long-term growth objectives. Integration planning is already in motion, and the company has reaffirmed its existing financial guidance.

Oxford BioMedica’s broader outlook remains positive, supported by recent earnings call insights and constructive corporate developments that signal confidence in its leadership and strategic direction. Nonetheless, ongoing financial performance pressures and valuation considerations temper some of the optimism.

About Oxford BioMedica

Oxford BioMedica is a global CDMO focused on advancing cell and gene therapies. With three decades of expertise in viral vector design, development, and production, the company partners with leading pharmaceutical and biotechnology organizations worldwide. Its end-to-end services cover the full lifecycle—from early development through to large-scale commercial manufacturing—underpinned by strong quality systems and regulatory compliance. Headquartered in Oxford, UK, the company operates facilities across the UK, France, and the United States.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

accesso Technology Group plc (LSE:ACSO), the premier technology solutions provider for attractions and venues worldwide, announced that on 1 October 2025, the Company granted the following conditional share awards over ordinary shares of 1 penny each of the Company  to Matthew Boyle (Chief Financial Officer) and Lee Cowie (Chief Operating Officer) under the accesso Technology Group 2024 Long Term Incentive Plan.

Matthew Boyle received 52,817 shares, taking his total holding to 134,030. Lee Cowie received 64,554 shares, taking his total holding to 121.255.

The award is consistent with previous annual awards to certain Directors of the Company under the LTIP and will vest three years from this date. No consideration will be paid for the conditional shares upon their vesting and the issuance of the Awards are subject to certain performance criteria. A summary of the performance criteria will be set out in the Directors’ Remuneration Report in the 2025 Annual Report and Accounts for the year which will be made available on the Company’s website.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Arecor Therapeutics plc (LSE:AREC) has announced changes to the Board, including the appointment of a new Chair to the Audit & Risk Committee and the elevation of the CFO to Executive Director, with immediate effect.

The biopharmaceutical company focuses on drug development and delivery in diabetes and other cardiometabolic diseases.

Simon Ormiston

Simon is a Chartered Accountant and former audit partner at PwC.  He has been appointed as a Non-Executive Director and the new Chair of the Audit & Risk Committee. In his c.30 years at PwC, of which more than half was spent as a partner, he specialised in financial accounting, reporting, auditing and risk management, focusing on the growth companies in the life sciences and technology sectors.  He has a strong track record of assisting both private and public companies to achieve their strategic ambitions, preparing for IPO and M&A transactions and strengthening governance.  His clients included those listed on AIM and the main market of the London Stock Exchange, as well as on other European and US exchanges.

Simon is taking on the Chair of the Audit & Risk Committee from Christine Soden, who has decided to step down from the Board and the Chair role, as part of the board succession plan.

David Ellam, CFO

David was appointed as interim CFO in November 2024, became full time CFO in February 2025 and is now moving onto the Board as Executive Director. He is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, Silence Therapeutics, and more recently, Sixfold Bioscience. He qualified as a Chartered Accountant at PwC.

Andy Richards, Chairman of Arecor said:

“I am pleased to welcome the two new members of the Arecor Board, Simon and David, and give a big thank you to Christine Soden. Chistine joined the Board at the IPO and has been a major support to the Company ever since. The Board is grateful for her contribution.

“Simon has had a long career at PwC and his knowledge of the financial markets, transactions and governance will be very valuable as we continue to grow Arecor. We also thank him for taking on the Chair position on the Audit & Risk Committee, an important role, especially in the life sciences sector. His insight as Arecor pursues its strategy to grow value will be especially helpful. To date, the Audit & Risk Committee has been ably overseen by Christine Soden who is now stepping away from Arecor. She will be missed by us all and we wish her all the best for the future.” 

“David has played a constructive and positive leadership role within the executive team at Arecor since he arrived a year ago, working closely with Sarah to run the day-to-day operations of the Company. Most recently, they have been working closely together to drive through the major strategic collaboration with Sequel around AT278 and the monetisation agreement with Ligand Pharmaceuticals. I look forward to having his broader input at the Board.” 

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

IXICO plc (LSE:IXI), has announced it will be hosting a Capital Markets Day for analysts and institutional investors.

The company is a global leaderin neuroscience imaging and biomarker analytics, and uses its AI-driven platform to help advance drug development in neurological disorders.

The Capital Markets Day will be on 30 October 2025, from 14:00 TO 17:00, at the offices of Cavendish Capital Markets.

The event will provide the opportunity to hear from IXICO’s CEO and strengthened senior management team, key customers and industry opinion leaders. The agenda will explore the Company’s growth strategy and future direction, the neuroscience landscape trends and expansion opportunities for the Company, IXICO’s technology roadmap and a detailed explanation of IXICO’s AI-driven precision medicine technology platform

Existing and prospective retail investors are welcome to join via a live webcast. The facility to submit questions will be available on this platform.

To register your interest please contact Cavendish Capital Markets on+44 (0) 20 7220 0500 or via email[email protected]

To register for the live webcast investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via: https://www.investormeetcompany.com/ixico-plc/register-investor

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.